Cardiovascular was the only business unit to grow by double digits last year, helping to fuel the overall medical device ...

Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.

Hollingshead, the former CEO of Insulet, will lead BVI as it uses a $1 billion financing to support its global eye care ...

Boston Scientific has told customers to stop using certain stents linked to three deaths, the Food and Drug Administration ...

Abbott’s latest CE mark for its TactiFlex Duo system was based on a clinical trial conducted in the European Union, United ...

Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between ...

Medtronic will integrate Precision Neuroscience’s Layer 7 cortical interface with its StealthStation surgical navigation ...

With the planned purchase, Boston Scientific will gain several thrombectomy devices to remove clots from blood vessels.

CEO Dave Rosa said a strong rollout for the da Vinci 5 surgical robot in 2025 exceeded expectations, with the system driving ...

The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...

An activist investor has reshaped the board, securing the departures of STAAR’s CEO and chair.

The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that ...